Skip to main content

Advertisement

Table 3 Results of repeat imaging at end of intended treatment period

From: Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

  Rivaroxaban 10 mg bid/15 mg od Rivaroxaban 15 mg bid/15 mg od Rivaroxaban combined UFH/warfarin
DVT patients N = 20 N = 23 N = 43 N = 12
Improved or normalized, n (%) 20 (100) 20 (87.0) 40 (93.0) 11 (91.7)
         Normalized 10 (50.0) 10 (43.5) 20 (46.5) 4 (33.3)
Unchanged, n (%) 0 2 (8.7) 2 (4.7) 1 (8.3)
Deteriorated, n (%) 0 1 (4.3) 1 (2.3) 0
         Asymptomatic 0 0 0 0
         Symptomatic* 0 1 (4.3) 1 (2.3) 0
PE patients - N = 28 N = 28 N = 7
Improved or normalized, n (%) - 28 (100) 28 (100) 6 (85.7)
         Normalized   24 (85.7) 24 (85.7) 2 (28.6)
Unchanged, n (%) - 0 0 0
Deteriorated, n (%) - 0 0 1 (14.3)
         Asymptomatic   0 0 1 (14.3)
         Symptomatic*   0 0 0
DVT and PE patients N = 20 N = 51 N = 71 N = 19
Improved or normalized, n (%) 20 (100) 48 (94.1) 68 (95.8) 17 (89.5)
         Normalized 10 (50.0) 34 (66.7) 44 (62.0) 6 (31.6)
Unchanged, n (%) 0 2 (3.9) 2 (2.9) 1 (5.3)
Deteriorated, n (%) 0 1 (2.0) 1 (1.4) 1 (5.3)
         Asymptomatic 0 0 0 1 (5.3)
         Symptomatic* 0 1 (2.0) 1 (1.4) 0
  1. bid, twice daily, DVT, deep vein thrombosis; od, once daily; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.
  2. *Symptomatic recurrent VTE during the entire intended treatment period.